{"organizations": [], "uuid": "253174f2611808bd6ab8c1861648736a0e292670", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-iovance-announces-preliminary-phas/brief-iovance-announces-preliminary-phase-2-data-for-til-treatment-in-head-and-neck-and-cervical-cancers-idUSFWN1PJ1CW", "country": "US", "domain_rank": 408, "title": "BRIEF-Iovance Announces Preliminary Phase 2 Data For Til Treatment In Head And Neck And Cervical Cancers", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-25T00:06:00.000+02:00", "replies_count": 0, "uuid": "253174f2611808bd6ab8c1861648736a0e292670"}, "author": "", "url": "https://www.reuters.com/article/brief-iovance-announces-preliminary-phas/brief-iovance-announces-preliminary-phase-2-data-for-til-treatment-in-head-and-neck-and-cervical-cancers-idUSFWN1PJ1CW", "ord_in_thread": 0, "title": "BRIEF-Iovance Announces Preliminary Phase 2 Data For Til Treatment In Head And Neck And Cervical Cancers", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "data for til treatment in head", "sentiment": "negative"}, {"name": "neck and cervical cancers reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "iovance biotherapeutics inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 24 (Reuters) - Iovance Biotherapeutics Inc:\n* IOVANCE BIOTHERAPEUTICS ANNOUNCES PRELIMINARY PHASE 2 DATA FOR TIL TREATMENT IN HEAD AND NECK AND CERVICAL CANCERS\n* 3 OF 8 PATIENTS TREATED WITH LN-145 HAD REDUCTION IN TUMOR SIZE OF AT LEAST 30 PCT & QUALIFIED AS PARTIAL RESPONSE\n* 1 OF 2 EVALUABLE PATIENTS WITH RECURRENT, METASTATIC/PERSISTENT CERVICAL CARCINOMA TREATED WITH LN-145 EXPERIENCED CONFIRMED PARTIAL RESPONSE WILL CONTINUE TO ENROLL PATIENTS IN STUDY TO FULL SAMPLE SIZE OF 47 PER PROTOCOL\n* ONE PATIENT TREATED WITH LN-145 HAD A CONFIRMED PR AND ONE HAD STABLE DISEASE AS PER PRELIMINARY DATA FROM C-145-04 STUDY\n* REPORTED PRELIMINARY CLINICAL RESULTS FROM TWO ONGOING OPEN-LABEL PHASE 2 STUDIES IN HEAD AND NECK AND CERVICAL CANCERS Source text for Eikon: Further company coverage:\n ", "external_links": [], "published": "2018-01-25T00:06:00.000+02:00", "crawled": "2018-01-25T00:23:08.016+02:00", "highlightTitle": ""}